Peritoneal Metastases from Colorectal Cancer: Treatment Principles and Perspectives

Diane Goéré; Isabelle Sourrouille; Maximiliano Gelli; Léonor Benhaim; Matthieu Faron; Charles Honoré

doi:10.1016/j.soc.2018.02.011

Peritoneal Metastases from Colorectal Cancer: Treatment Principles and Perspectives

Surg Oncol Clin N Am. 2018 Jul;27(3):563-583. doi: 10.1016/j.soc.2018.02.011.

Authors

Diane Goéré¹, Isabelle Sourrouille², Maximiliano Gelli², Léonor Benhaim², Matthieu Faron², Charles Honoré²

Affiliations

¹ Department of Visceral and Oncological Surgery, Gustave Roussy, Cancer Campus, Villejuif Cedex 94805, France. Electronic address: diane.goere@gustaveroussy.fr.
² Department of Visceral and Oncological Surgery, Gustave Roussy, Cancer Campus, Villejuif Cedex 94805, France.

PMID: 29935690
DOI: 10.1016/j.soc.2018.02.011

Abstract

Peritoneal metastases are the third most common site of recurrence of colorectal cancer. Diagnosis is difficult and often made at an advanced stage even on imaging. Curative treatment relies on complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC), which dramatically improves survival in selected patients. Main prognostic factors are based on the extent of the peritoneal disease and the completeness of surgery. Therefore, identifying patients at high risk of developing peritoneal metastases with the aim of diagnosing and treating patients at an early stage appears crucial. Proactive attitude and prophylactic treatment based on HIPEC are being evaluated on clinical trials.

Keywords: Carcinomatosis; Colorectal cancer; HIPEC; Peritoneal metastases.

Publication types

Review

MeSH terms

Colorectal Neoplasms / pathology*
Colorectal Neoplasms / therapy*
Combined Modality Therapy
Humans
Peritoneal Neoplasms / secondary*
Peritoneal Neoplasms / therapy*
Treatment Outcome